Air pollution poses a significant environmental health risk, resulting in approximately 6.7 million premature deaths annually due to both ambient and household air pollution....
The US is facing a fourth wave of COVID-19, as emergency healthcare workers across the country continue to face the virus and experience levels of burnout that can lead to PTSD.
New CDC guidelines suggest that surfaces are a "low-risk" for COVID transmission - cleaning surfaces with detergent or soap once a day should be enough to reduce possible virus levels.
Chris Norton, Managing Director, UK & Ireland, InterSystems, discusses the NHS’ current challenges, integrated care efforts, and the ways data and technology can be harnessed to inform care today, and in a post-COVID world.
New data from the REACT study finds that the prevalence of COVID is down by 60% in one month, but primary school children have the highest COVID infection levels.
Scientists have developed an implantable sensor using gold nanoparticles, which can function in the human body for "several months" to report health changes.
Researchers have discovered a deadly new snake species in Asia, which has been named Suzhen's krait after the mythical figure of Bai Su Zhen - a snake goddess who saved a lot of human lives.
There is little mainstream awareness of the condition that impacts one in ten women - currently, 30% of people with Polycystic ovary syndrome (PCOS) rely on online forums for information.
We spoke with Dr Matthew Duchars, CEO of the UK’s first dedicated Vaccines Manufacturing and Innovation Centre (VMIC), about their work not only to provide an integral response to COVID-19, but as a centre of excellence advancing the vaccine sector on a global scale.
A "human error" created a factory mixup for Johnson & Johnson in Baltimore, Maryland, damaging up to 15 million vaccine doses - but this does not impact doses that are ready for use.
Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.
Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, provide an in-depth perspective on Huntington’s disease (HD) research.
Sue Johnson Gregory, principal consultant, and Tim Powlson, senior business consultant at Entec Si, explain how to build a stronger, more joined up workforce in the face of future healthcare crises.
